Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
1.040
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Sep 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
Next >
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
September 07, 2021
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
July 28, 2021
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Supply Chain
Exposures
Intellectual Property
Supply Chain
Lexaria Completes Dosing in Human Clinical Study HYPER-H21-2
July 27, 2021
Additionally, second patent award received in Japan KELOWNA, BC / ACCESSWIRE / July 27, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives US$3,817,643 From Warrant Exercises
July 26, 2021
KELOWNA, BC / ACCESSWIRE / July 26, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Summarizes Successful Antiviral Drug Studies and Ongoing Strategy
July 22, 2021
All objectives evaluating DehydraTECH™ drug delivery platform successfully achieved KELOWNA, BC / ACCESSWIRE / July 22, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Death
Intellectual Property
Exposures
Animal Testing
COVID-19
Death
Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3
July 21, 2021
Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Exposures
Animal Testing
COVID-19
Intellectual Property
Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council
July 15, 2021
VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan
July 13, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Receives Patent Protection in Japan
July 13, 2021
New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets
July 05, 2021
KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces 2021 Annual Meeting Results
June 29, 2021
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 15, 2021
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
June 09, 2021
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Exposures
Animal Testing
COVID-19
Intellectual Property
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
June 07, 2021
- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
June 03, 2021
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
May 20, 2021
- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Exposures
Animal Testing
Intellectual Property
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
May 12, 2021
- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
May 07, 2021
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
May 06, 2021
- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Commences Human Clinical Hypertension Study
April 22, 2021
- Study to examine DehydraTECHTM CBD's ability to control blood pressure - First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
April 15, 2021
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network
April 14, 2021
- DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Supply Chain
Exposures
Intellectual Property
Supply Chain
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.